MX2013004693A - Composiciones de aripiprazol y metodos para su suministro transdermico. - Google Patents

Composiciones de aripiprazol y metodos para su suministro transdermico.

Info

Publication number
MX2013004693A
MX2013004693A MX2013004693A MX2013004693A MX2013004693A MX 2013004693 A MX2013004693 A MX 2013004693A MX 2013004693 A MX2013004693 A MX 2013004693A MX 2013004693 A MX2013004693 A MX 2013004693A MX 2013004693 A MX2013004693 A MX 2013004693A
Authority
MX
Mexico
Prior art keywords
transdermal delivery
methods
aripiprazole compositions
aripiprazole
compositions
Prior art date
Application number
MX2013004693A
Other languages
English (en)
Other versions
MX339196B (es
Inventor
Fotios M Plakogiannis
Muhammed Anwar Hossain
Original Assignee
Transdermal Res Pharm Lab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transdermal Res Pharm Lab Llc filed Critical Transdermal Res Pharm Lab Llc
Publication of MX2013004693A publication Critical patent/MX2013004693A/es
Publication of MX339196B publication Critical patent/MX339196B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Secondary Cells (AREA)

Abstract

La presente invención divulga composiciones de formulación líquida y de gel que contienen aripiprazol en la forma de un parche para el suministro transdérmico.
MX2013004693A 2010-10-28 2011-10-20 Composiciones de aripiprazol y metodos para su suministro transdermico. MX339196B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40759110P 2010-10-28 2010-10-28
PCT/US2011/057080 WO2012058091A2 (en) 2010-10-28 2011-10-20 Aripiprazole compositions and methods for its transdermal delivery

Publications (2)

Publication Number Publication Date
MX2013004693A true MX2013004693A (es) 2013-11-01
MX339196B MX339196B (es) 2016-05-16

Family

ID=45994667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004693A MX339196B (es) 2010-10-28 2011-10-20 Composiciones de aripiprazol y metodos para su suministro transdermico.

Country Status (11)

Country Link
US (2) US9138402B2 (es)
EP (1) EP2632463B1 (es)
JP (2) JP5966228B2 (es)
CN (2) CN103491961B (es)
AU (1) AU2011320758B2 (es)
BR (1) BR112013010190B1 (es)
CA (1) CA2816203C (es)
ES (1) ES2675913T3 (es)
MX (1) MX339196B (es)
RU (1) RU2589689C2 (es)
WO (1) WO2012058091A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
WO2014172344A1 (en) * 2013-04-16 2014-10-23 Alpha To Omega Pharmaceutical Consultants, Inc. Pharmaceutical compositions
US10356018B2 (en) 2014-01-31 2019-07-16 Vivint, Inc. User management methods and systems
WO2016200830A1 (en) * 2015-06-08 2016-12-15 Corium International, Inc. Formulations for aripiprazole delivery transdermally
WO2017025912A1 (en) * 2015-08-13 2017-02-16 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
EP3448387A4 (en) * 2016-04-25 2019-12-11 Otsuka Pharmaceutical Co., Ltd. PHARMACEUTICAL PRODUCT COMPOSITIONS COMPRISING AN INGREDIENT EVENT MARKER
WO2017195897A1 (ja) * 2016-05-12 2017-11-16 富士フイルム株式会社 経皮製剤
WO2018117125A1 (ja) * 2016-12-19 2018-06-28 富士フイルム株式会社 経皮製剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101492A0 (en) 1992-04-03 1992-12-30 Shalom Levy Anti-skin rash preparation
US5616602A (en) * 1993-07-09 1997-04-01 Ciba-Geigy Corporation Topically administrable zinc phthalocyanine compositions
EP0668074B1 (de) * 1994-02-18 2001-05-09 Drossapharm AG Transdermales therapeutisches System
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
DE10030716A1 (de) * 2000-06-23 2002-01-03 Degussa Tieftemperaturschlagzähe Polymerlegierung
DE10110953A1 (de) * 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten
US20040170672A1 (en) * 2001-03-07 2004-09-02 Thorsten Selzer Transdermal therapeutic system for administration of partial dopamine-d2 agonists
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
CN1870980B (zh) * 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
PL1613598T3 (pl) 2003-12-16 2012-03-30 Teva Pharma Sposób wytwarzania krystalicznych form aripiprazolu
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
EP2066699B1 (en) * 2006-09-25 2020-02-12 Archer-Daniels-Midland Company Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same
WO2008041246A2 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and its' process of preparation
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
CN104224703A (zh) * 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
GB0905365D0 (en) * 2009-03-27 2009-05-13 Norbrook Lab Ltd A topical parasiticide composition
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
JP5664871B2 (ja) * 2009-06-19 2015-02-04 株式会社 メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
US9358261B2 (en) * 2011-10-25 2016-06-07 U.S. Phytotherapy, Inc. Additional artemisinin and berberine compositions and methods of making
US9968740B2 (en) * 2014-03-25 2018-05-15 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US9468206B2 (en) * 2014-12-31 2016-10-18 Valent U.S.A., Corporation Lactofen and dicamba diglycol amine liquid formulations

Also Published As

Publication number Publication date
EP2632463A4 (en) 2016-04-20
JP2014503479A (ja) 2014-02-13
EP2632463A2 (en) 2013-09-04
US9138402B2 (en) 2015-09-22
WO2012058091A3 (en) 2013-10-17
WO2012058091A2 (en) 2012-05-03
CN107929239A (zh) 2018-04-20
ES2675913T3 (es) 2018-07-13
US20130171237A1 (en) 2013-07-04
JP5966228B2 (ja) 2016-08-10
US20130209552A1 (en) 2013-08-15
BR112013010190B1 (pt) 2019-12-31
RU2013124401A (ru) 2014-12-10
RU2589689C2 (ru) 2016-07-10
CN103491961B (zh) 2018-01-02
CA2816203A1 (en) 2012-05-03
CN107929239B (zh) 2021-06-01
EP2632463B1 (en) 2018-04-04
AU2011320758B2 (en) 2015-09-24
MX339196B (es) 2016-05-16
BR112013010190A2 (pt) 2016-09-13
JP2016164204A (ja) 2016-09-08
CA2816203C (en) 2017-02-21
CN103491961A (zh) 2014-01-01
AU2011320758A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
MX339196B (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
HK1245130A1 (zh) 酶組合物及其用於創傷愈合的用途
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
GB201106750D0 (en) Novel compounds
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
HK1182010A1 (en) Liquid pharmaceutical composition for the delivery of active ingredients
HK1210939A1 (en) Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
IL226327A (en) Nephrilicin inhibitors, pharmaceuticals containing them, and their use in the preparation of such preparations
IN2014CN00568A (es)
IL236268A0 (en) Preparations for mucosal administration and their uses
EP3130583C0 (en) KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
PH12015501302A1 (en) Compositions comprising vortioxetine and donepezil
HK1249519A1 (zh) Hsp90c端抑制劑及其醫藥組合物和用途
EP2938391A4 (en) TRANSDERMAL BUPRENORPHINE COMPOSITIONS WITH DELAYED RELEASE AND METHOD OF USE THEREOF
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
MX2014008693A (es) Administracion transdermica de hormonas.
EP2908800B8 (en) Composition and delivery vehicle for active agents and methods therefor
EA201391703A1 (ru) Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма
AU2012902180A0 (en) Methods for Prepartion and Delivery of Fuel Compositions
AU2012901190A0 (en) Liposome Compositions and Systems for Drug Delivery

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: AEQUUS PHARMACEUTICALS INC.